Staphylococcal Meningitis Treatments

Find Staphylococcal Meningitis Treatments

Receiving a diagnosis of staphylococcal meningitis is a medical emergency that can be terrifying for patients and their families. Unlike some other forms of meningitis, this bacterial infection often develops following a head injury, neurosurgery, or as a complication of medical devices like shunts. The sudden onset of severe headaches, high fever, stiffness in the neck, and confusion creates a situation where every minute counts. While the diagnosis is serious, immediate and aggressive treatment is essential to eliminate the bacteria, reduce dangerous swelling around the brain, and prevent long-term neurological damage. 

Because this type of meningitis is frequently associated with hospital procedures or foreign bodies in the body, treatment is complex and often requires a multidisciplinary team. The choice of medication is strictly guided by the specific strain of Staphylococcus bacteria identified whether it is sensitive to standard antibiotics or resistant, such as Methicillin-resistant Staphylococcus aureus (MRSA). Treatment plans must be aggressive and are tailored to the patient’s history, kidney function, and the presence of any implanted medical hardware (National Institute of Neurological Disorders and Stroke, 2023). 

Overview of treatment options for Staphylococcal Meningitis 

The primary goal of treating staphylococcal meningitis is to eradicate the bacterial infection from the cerebrospinal fluid and the bloodstream. This requires high doses of intravenous (IV) antibiotics that can effectively cross the blood-brain barrier to reach the infection site. 

Treatment is almost exclusively hospital-based, often requiring intensive care monitoring. While antibiotics are the engine of recovery, doctors may also use corticosteroids to manage inflammation. If the infection is caused by an infected shunt or catheter, medications alone are often insufficient, and surgical removal or replacement of the device is typically required alongside drug therapy. 

Medications used for Staphylococcal Meningitis 

Doctors rely on potent antibiotics to fight this resilient bacteria. The regimen typically begins with broad-spectrum drugs and is narrowed down once lab results confirm the specific bacterial strain. 

Glycopeptides are the standard first-line defense, particularly before the exact bacterial strain is known or if MRSA is suspected. Vancomycin is the most widely used drug in this class. It is chosen for its ability to treat resistant strains of staph that other antibiotics cannot kill. Clinical experience suggests that vancomycin is the cornerstone of empiric therapy for healthcare-associated meningitis until specific testing is complete. 

Penicillinase-resistant penicillins are preferred if testing confirms the bacteria is Methicillin-sensitive Staphylococcus aureus (MSSA). Drugs such as nafcillin or oxacillin are often used in these cases. These medications are typically more effective than vancomycin against non-resistant strains and are able to penetrate the central nervous system effectively in the presence of inflammation. 

Rifamycins are often added as an adjunctive or “helper” therapy rather than used alone. Rifampin is frequently prescribed in combination with vancomycin. Its unique ability to penetrate biofilms, sticky protective layers that bacteria form on medical devices like shunts and drains, makes it valuable for treating device-related infections (Merck Manual, 2022). 

How these medications work 

The medications used for staphylococcal meningitis target the bacteria’s physical structure and ability to reproduce. 

Glycopeptides like vancomycin kill bacteria by inhibiting cell wall construction, causing instability and death. This is vital against resistant strains.  

Penicillins also target the cell wall but bind to different proteins, preventing cross-linking needed for the outer shell, leading to cell rupture and death.  

Rifamycins, however, enter the cell and block the enzyme creating RNA, halting protein production. This effectively shuts down the infection and spread, especially in medical device colonies. 

Side effects and safety considerations 

Because treatment involves high doses of potent IV antibiotics, side effects must be monitored closely. 

Vancomycin risks include kidney strain (nephrotoxicity), especially in older adults or with other medications, and “Red Man Syndrome” (flushing/itching) if infused too fast. Drug levels and kidney function require regular blood tests. 

Nafcillin and oxacillin can cause liver stress or temporary neutropenia. Rifampin turns bodily fluids (like urine/tears) reddish-orange, which is harmless but can be concerning. It requires a full medication review due to potential drug interactions. 

Difficulty breathing, hives, or swelling require immediate medical attention as they may signal an allergic reaction. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov 
  1. Merck Manual. https://www.merckmanuals.com 
  1. Meningitis Research Foundation. https://www.meningitis.org 
  1. Mayo Clinic. https://www.mayoclinic.org 

Medications for Staphylococcal Meningitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Staphylococcal Meningitis.

Found 4 Approved Drugs for Staphylococcal Meningitis

CefTRIAXone

Generic Name
CefTRIAXone

CefTRIAXone

Generic Name
CefTRIAXone
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media Caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy. Skin and Skin Structure Infections Caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species. Urinary Tract Infections (complicated and uncomplicated) Caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea (cervical/urethral and rectal) Caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. Pelvic Inflammatory Disease Caused by Neisseria gonorrhoeae. Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone and Joint Infections Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-abdominal Infections Caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis Caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis * and Escherichia coli*. *Efficacy for this organism in this organ system was studied in fewer than ten infections. Surgical Prophylaxis The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Arikayce

Generic Name
Amikacin

Arikayce

Generic Name
Amikacin
LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. LIMITED POPULATION: ARIKAYCE is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. ( 1 ) This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. ( 1 ) Limitation of Use: ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease. Limitation of Use : ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Ceftazidime

Brand Names
Avycaz, Tazicef

Ceftazidime

Brand Names
Avycaz, Tazicef
AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients aged 3 months and older: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole.

Minocycline

Brand Names
Amzeeq, Arestin, Emrosi, Minocin, ZILXI

Minocycline

Brand Names
Amzeeq, Arestin, Emrosi, Minocin, ZILXI
AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances